Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: Evaluation of the direct thrombin inhibitor ximelagatran

J. H. Lewis, D. Larrey, R. Olsson, W. M. Lee, L. Frison, M. Keisu

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint Dive into the research topics of 'Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: Evaluation of the direct thrombin inhibitor ximelagatran'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds